Technology | Lung Cancer | April 26, 2016

FDA Clears Philips CT Solutions for Lung Cancer Screening

Company’s full suite of low-dose CT solutions now cleared for lung cancer screening to promote early detection

Philips, low-dose CT, lung cancer screening, FDA approval

April 26, 2016 — Philips announced that any hospital or healthcare facility with one of its indicated computed tomography (CT) models can now become a lung cancer screening center. Philips’ suite of CT solutions has achieved 510(k) clearance from the U.S. Food and Drug Administration (FDA) for low-dose lung cancer screening (LCS).

The suite includes 27 CT and positron emission tomography (PET)/CT models, as well as integrated software and services.

Lung cancer is the leading cause of cancer death among both men and women in the United States, and the source of one in four cancer deaths. Screenings are recommended by the Center for Medicare & Medicaid Services (CMS) to help identify the disease earlier in high-risk populations when treatment can be more successful. Early detection using this method has been shown to not only improve prognosis and treatment but decrease death rates up to 20 percent. In addition, if diagnosed in stage one, patients can have up to a 49 percent chance of surviving, compared to a diagnosis at stage three where the survival rate is as low as 5 percent.

“Lung cancer is the No. 1 cancer killer in America, taking more American lives than colon, breast and prostate cancer combined, and early detection is key to fighting this terrible disease,” said Brady J. McKee, M.D., radiologist at Lahey Hospital and Medical Center, which features the largest clinical lung cancer screening program in the country. “The work Philips has done to improve a provider’s screening capability not only benefits individual patients, but hospitals at each step of their Lung Cancer Screening program implementation and execution, which is often a very complicated process that includes community outreach, physician education, patient and data management, and reporting.”

Philips’ low-dose CT solutions now give healthcare organizations of varying clinical and economic needs — from community hospitals to multi-facility health systems — the ability to build robust lung cancer screening programs. Through its integrated radiology solutions and services, Philips can work with healthcare executives to better assess availability of existing scanners and to establish an enterprise-wide lung cancer program that will deliver advanced patient care and access.

Philips lung cancer screening solutions also provide several benefits for patients and referring physicians, including:

  • Personalized management of radiation dose – The 27 models of Philips CT and PET/CT solutions qualified with the indications for use to perform CT lung cancer screening also utilize active dose management tools;
  • Greater insights throughout the process – Referring physicians are better able to manage the process from end-to-end through “control center” software tools that enable digital access to patient tracking data that proves insight into scheduling, results and follow-up activities; and
  • Advanced image data sharing and analytics – Through its IntelliSpace Portal, Philips offers a comprehensive solution for detection, diagnostics and therapy follow-up. To address the increasing interest in pulmonary care, the latest version, IntelliSpace Portal 8.0, now includes the new CT Lung Nodule Assessment (LNA) application designed for a more efficient and longitudinal workflow to provide additional clinical decision support. 

For more information: www.medical.philips.com

Related Content

Video Plus Brochure Helps Patients Make Lung Cancer Scan Decision

Image courtesy of the American Thoracic Society

News | Lung Cancer | April 19, 2019
A short video describing the potential benefits and risks of low-dose computed tomography (CT) screening for lung...
FDA Clears GE's Deep Learning Image Reconstruction Engine
Technology | Computed Tomography (CT) | April 19, 2019
GE Healthcare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) of its Deep Learning Image...
Oxipit Introduces Multilingual Support for ChestEye AI Imaging Suite
News | Artificial Intelligence | April 16, 2019
The CE-certified ChestEye artificial intelligence (AI) imaging suite by Oxipit is now available in seven European...
Enlitic Closes Series B Funding for Artificial Intelligence Solutions for Radiologists
News | Artificial Intelligence | April 08, 2019
Radiology artificial intelligence (AI) company Enlitic announced the close of its $15 million Series B financing round...
Videos | RSNA | April 03, 2019
ITN Editor Dave Fornell takes a tour of some of the most interesting new medical imaging technologies displa
Johns Hopkins Medicine First in U.S. to Install Canon Medical's Aquilion Precision
News | Computed Tomography (CT) | March 26, 2019
March 26, 2019 — Johns Hopkins Medicine now has access to the first...
At #ACC.19, Siemens unveiled a version of its go.Top platform optimized for cardiovascular imaging. The newly packaged scanner can generate the data needed to do CT-based FFR (fractional flow reserve).

At #ACC.19, Siemens unveiled a version of its go.Top platform optimized for cardiovascular imaging. The newly packaged scanner can generate the data needed to do CT-based FFR (fractional flow reserve). Photo by Greg Freiherr

Feature | Cardiac Imaging | March 22, 2019 | By Greg Freiherr
Reflecting a trend toward the increased use of...
Researchers Use Radiomics to Predict Who Will Benefit from Chemotherapy
News | Radiomics | March 21, 2019
Using data from computed tomography (CT) images, researchers may be able to predict which lung cancer patients will...
HeartFlow Analysis Successfully Stratifies Heart Disease Patients at One Year
News | CT Angiography (CTA) | March 19, 2019
Late-breaking results confirm the HeartFlow FFRct (fractional flow reserve computed tomography) Analysis enables...
Podcast | Cardiac Imaging | March 15, 2019
Debate About Coronary Testing Highlights ACC Session